Figure 2From: A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancerBefore and after images of Abound™ treatment: lower limbs. (a) Before Abound™ was administered (CTCAE version 4.0: Grade 2). (b) After Abound™ was administered (CTCAE version 4.0: Grade 0). CTCAE, common terminology criteria for adverse events.Back to article page